Actively Recruiting
Buprenorphine for Individuals in Jail
Led by Friends Research Institute, Inc. · Updated on 2026-02-03
240
Participants Needed
2
Research Sites
234 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail. An open-label design will randomly assign 240 adults with moderate-to-severe OUDs who are soon-to-be-released from jail to either XR-B (n=120) or SL-B (n=120) treatment in jail followed by 6-months of post-release buprenorphine treatment, a 7-month safety visit, and a final long-term follow-up at 12-months.
CONDITIONS
Official Title
Buprenorphine for Individuals in Jail
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult male or female inmates at participating jail who are eligible for release within 120 days (sentenced and/or pretrial; individuals who might be sentenced to state/federal prison will be excluded)
- Individuals completing their sentence in the community under probation, parole, home detention, electronic monitoring, drug or other treatment court (or equivalent) are eligible
- History of moderate or severe opioid use disorder (DSM-5 criteria) at incarceration, or treated in opioid agonist program during the year before incarceration
- Medically suitable for extended-release or sublingual buprenorphine treatment
- Willing to enroll in buprenorphine treatment in jail and continue after release
- Planning to live in Baltimore City or the Baltimore Region
You will not qualify if you...
- Liver function test levels greater than 5 times normal (or as determined by study physician if labs unavailable)
- Active medical illness that may make participation hazardous (e.g., unstable diabetes, heart disease, moderate to severe renal impairment); adequately treated conditions allowed
- Conditions or medications that may cause QTc prolongation (e.g., long QT syndrome, hypokalemia, certain antibiotics, antifungals, anti-arrhythmics, antipsychotics, antidepressants)
- Untreated psychiatric disorders that may make participation hazardous (e.g., untreated psychosis, bipolar disorder with mania); adequately treated disorders and psychotropic medications allowed
- History of allergic reaction to buprenorphine
- Suicidal ideation within the past 6 months
- Inability to pass a study enrollment quiz
- Currently receiving non-buprenorphine medication for opioid use disorder in jail (e.g., methadone, naltrexone)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Friends Research Institute
Baltimore, Maryland, United States, 21201
Actively Recruiting
2
Baltimore Central Booking & Intake Center
Baltimore, Maryland, United States, 21202
Actively Recruiting
Research Team
M
Michael Gordon, DPA
CONTACT
T
Thomas R Blue, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here